Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an Early Feasibility Study to evaluate the usability, safety and functionality of 3D holographic guidance, navigation, and control (3D-GNC) as an adjunct to and confirmed by fluoroscopic imaging to be used with Cook Zenith Flex AAA Endovascular Graft.
Full description
The goal of this clinical study is to evaluate the feasibility of using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of the following: 1) experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS), 2) FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system and 3) 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2. Planning and execution of each case will be major steps in demonstrating feasibility of the technology beyond non-clinical and preclinical testing.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The patient meets the instructions for use (IFU) for the 24-28 mm body Cook Zenith Flex AAA bifurcated stent graft.
i. With a length of at least 15mm ii. With a diameter measured outer wall to outer wall of no greater than 26mm and no less than 20mm iii. With an angle less than 60 degrees relative to the long access of the aneurysm and iv. With an angle less than 45 degrees relative to the axis of the suprarenal aorta c. Iliac artery distal fixation site greater than 10mm in length and 7.5-20mm in diameter (measured outerwall to outerwall).
Male/female, aged ≥ 18
Patient fulfilling criteria for needing endovascular repair of abdominal aortic aneurysm according to routine clinical practice criteria of the participating center
Women of childbearing potential must be non-pregnant, non-lactating, and not planning to become pregnant during the course of the trial; and have a negative urine or serum pregnancy test within 7 days prior to index procedure
Provide written informed consent as applicable and defined by site country regulation
Stated willingness to comply with all study procedures and availability for the duration of the study
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
Contraindications for Cook Zenith Flex Aortic endograft:
Presence of electronic implants, e.g., cardiac pacemaker, AICD or nerve stimulator
Presence of metallic implants above the knee, e.g., artificial hip
Patients not willing or able to give informed consent
Pregnant women
Patients' inability to have a contrasted CT scan
Current or planned participation in any other investigational drug or medical device clinical study that has not completed primary endpoint(s) evaluation;
Other medical, social, or psychological issues that in the opinion of the investigator preclude the subjects from receiving this treatment, and the procedures and evaluations pre- and posttreatment
Anatomy outside of the IFU for a 24-28 mm Cook Zenith Flex AAA bifurcated stent graft
Primary purpose
Allocation
Interventional model
Masking
3 participants in 1 patient group
Loading...
Central trial contact
Francis Caputo, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal